A pre-commercial biopharmaceutical firm advancing oncology and immunology candidates through a proprietary discovery platform with minimal current revenue but significant cash reserves.
Investors might consider Silo Pharma if they believe in the transformative potential of its proprietary drug discovery platform to identify the next blockbuster cancer therapies. The company's ability to raise capital through financing and share issuances provides a safety net that allows it to pursue high-risk, high-reward projects without immediate commercial pressure. If any clinical candidates show promising data, the current lack of competition in early-stage oncology assets could lead to significant value accretion upon partnership or sale.
The stock is a speculative gamble given the consistent deep losses and a revenue base that is effectively non-existent for two consecutive years. Investors face a high probability of dilution through frequent share issuances as the company attempts to extend its cash runway against mounting operating expenses. Without a clear path to commercialization or a confirmed major partnership, the risk of capital erosion outweighs the potential upside in this highly volatile pre-revenue environment.
Silo Pharma, Inc. is a biopharmaceutical company focused on developing novel drug discovery technologies and therapeutic candidates primarily for oncology and inflammatory diseases. The company leverages its proprietary platform to advance clinical-stage assets while generating limited revenue from early-stage licensing or product sales. Operations are centered on high-risk R&D investments aimed at transforming early science into potential life-saving therapies.
Management has prioritized research and development spending at $2.4 million alongside share-based compensation nearing $1 million, resulting in a significant operating cash outflow of $3.8 million for the latest period. Despite these heavy investments, the company managed to increase its cash reserves slightly through financing activities totaling $3.2 million, though the accumulated deficit continues to widen year over year. The revenue stream remains negligible at roughly $0.1 million, indicating that the business model is entirely dependent on future licensing deals or commercialization success rather than current product sales.
The biopharmaceutical industry is characterized by long development cycles and high failure rates, particularly for companies targeting oncology and immunology where competition is fierce. Market leaders often rely on massive budgets to navigate clinical trials, whereas smaller players like Silo Pharma depend on strategic partnerships and licensing deals to achieve financial sustainability. Regulatory hurdles remain stringent, requiring substantial investment in safety and efficacy data before any product can reach the market.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $72.1K | $72.1K |
| Cost of Revenue | $5.8K | $5.8K | $5.8K |
| Gross Profit | $66.3K | $66.3K | $66.3K |
| Operating Expenses | $3.7M | $3.9M | $4.8M |
| Operating Income | $-3.6M | $-3.9M | $-4.7M |
| R&D | $1.3M | $845.1K | $2.4M |
| G&A | $227.3K | $390.1K | — |
| Stock-Based Comp | $577.7K | $871.6K | $906.8K |
| Other OpEx | $2.2M | $2.7M | $2.4M |
| Non-Operating Income | $-279.7K | $224.5K | $312.8K |
| Interest Expense | $2.2K | $4.9K | — |
| Pre-Tax Income | $-3.9M | $-3.6M | $-4.4M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-3.9M | $-3.6M | $-4.4M |
| Discontinued Ops | $-1.2K | $-69.6K | $0 |
| Net Income | $-3.9M | $-3.7M | $-4.4M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-3.9M | $-3.7M | $-4.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $11.6M | $7.7M | $7.1M |
| Cash & Equivalents | $11.4M | $3.5M | $3.9M |
| Marketable Securities | — | $4.1M | $3.2M |
| Prepaid Expenses | $135.9K | $16.0K | $31.0K |
| Other Current Assets | $69.1K | $0 | $0 |
| Long-Term Assets | $70.8K | $65.0K | $300.4K |
| Intangibles | — | — | $241.2K |
| Other LT Assets | $67.7K | — | $59.1K |
| Total Assets | $11.6M | $7.7M | $7.4M |
| Current Liabilities | $436.3K | $775.6K | $1.7M |
| Deferred Revenue | — | — | $72.1K |
| Other Current Liab | — | — | $1.6M |
| Long-Term Liabilities | $865.8K | $793.7K | $721.6K |
| Other LT Liab | — | — | $0 |
| Total Liabilities | $1.3M | $1.6M | $2.4M |
| Shareholders' Equity | $10.3M | $6.2M | $5.0M |
| Paid-In Capital | $17.5M | — | $20.3M |
| Retained Earnings | $-7.2M | $-10.9M | $-15.3M |
| AOCI | — | $-6.2K | $2.4K |
| Total L&E | $11.6M | $7.7M | $7.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-3.9M | $-3.7M | $-4.4M |
| Non-Cash Adjustments | $497.2K | $241.1K | $-11.1K |
| Working Capital Changes | $-86.3K | $235.1K | $570.1K |
| Cash from Operations | $-3.5M | $-3.2M | $-3.8M |
| Cash from Investing | $86.7K | $-4.1M | $973.8K |
| Cash from Financing | $4.9M | $-471.1K | $3.2M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $1.5M | $-7.8M | $381.5K |
| Beginning Cash | $9.8M | $11.4M | $3.5M |
| Ending Cash | $11.4M | $3.5M | $3.9M |
The company operates primarily through its drug discovery and development segment, focusing on internal research programs for cancer and autoimmune indications. A secondary revenue stream involves potential licensing agreements or collaborations that are currently in early stages, reflected by low current revenue figures relative to operating expenses. The financial structure also reflects a heavy reliance on financing activities to fund ongoing R&D efforts rather than commercial sales.
The company faces significant financial risk due to persistent net losses of approximately $4.4 million annually and a substantial accumulated deficit of $15.3 million. Cash burn rates are high relative to the current cash position, creating uncertainty about liquidity runway without additional financing or successful asset sales. There is no guarantee that any drug candidates will successfully complete clinical trials or obtain regulatory approval, which could result in total loss of invested capital. The lack of commercial revenue makes the stock highly sensitive to market conditions and investor sentiment toward biotech firms.
Silo Pharma possesses a proprietary drug discovery platform that may accelerate the identification of novel therapeutic targets compared to traditional large pharma approaches. The company maintains a lean operational model with limited current liabilities, allowing for strategic flexibility in capital allocation during early development phases. Its focus on unmet medical needs in oncology provides access to a high-value market segment with substantial potential upon successful regulatory approval.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.